Skip to content

The Prognostic Impact of COVID-19 Incidence, the Effectiveness of SARS-CoV-2 Vaccine, and Factors that may Prevent Vaccination in Japanese Dialysis Patients

The Prognostic Impact of COVID-19 Incidence, the Effectiveness of SARS-CoV-2 Vaccine, and Factors that may Prevent Vaccination in Japanese Dialysis Patients - The Impact of COVID-19 on Dialysis Patients and Factors Associated with its Vaccination.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000052167
Enrollment
365000
Registered
2023-09-25
Start date
2023-10-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage kidney disease under hemodialysis therapy

Interventions

None listed

Sponsors

The University of Tokyo Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: In the database study, all patients included in the Japan Society for Dialysis Therapy statistical survey who are at least 18 years old, have been on dialysis for at least 3 months, and meet the criteria of 3 dialysis cycles per week. In the questionnaire survey, patients who meet the following criteria: age 18 years or older, dialysis history of at least 3 months, and number of dialysis cycles per week of times per week, among the patients who are currently attending the study's collaborating institution. In the interview survey, patients who were unvaccinated or who were unvaccinated but were vaccinated based on some trigger among the patients who participated in the questionnaire survey.

Exclusion criteria

Exclusion criteria: In any survey, if the applicant is under 18 years of age. In addition, if the person is determined to lack the capacity to give informed consent, for example, if he/she has a diagnosis of dementia.

Design outcomes

Primary

MeasureTime frame
COVID-19 morbidity and mortality after COVID-19 vaccination

Secondary

MeasureTime frame
Cardiovascular disease incidence after COVID-19 morbidity Mortality after COVID-19 incidence Cardiovascular disease incidence after COVID-19 vaccination

Countries

Japan

Contacts

Public ContactYuka Sugawara

The University of Tokyo Hospital Division of Nephrology and Endocrinology

jinnai.research.assist@gmail.com03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026